H.C. Wainwright assumed coverage of Moleculin Biotech (MBRX) with a Buy rating and $4 price target Moleculin is a clinical-stage biotech company advancing treatments for highly resistant cancers and viruses, the analyst tells investors in a research note. The firm says the MIRACLE Part A data could position annamycin for accelerated approval in second-line acute myeloid leukemia.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBRX:
- Moleculin Biotech: Positive Clinical Trial Results and Strategic Developments Support Buy Rating
- Moleculin Biotech Hosts Key Opinion Leaders Event
- Moleculin Biotech releases KOL webcast to discuss Phase 1B/2 annamycin data
- Moleculin Biotech Stock (MBRX) Dives 10% on Clinical Trial Results
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories